MELALITE XL is a combination dermatological medicine primarily used for the short-term treatment of moderate to severe facial melasma. It contains three active ingredients with complementary mechanisms of action.
Hydroquinone reduces melanin production and helps lighten areas of hyperpigmentation. Tretinoin is a retinoid that promotes epidermal cell turnover and may improve the penetration of hydroquinone into the skin. Mometasone furoate is a topical corticosteroid that reduces inflammatory responses and may help limit irritation associated with the other active ingredients. (Springer)
The medication may be prescribed for patients:
Clinical research has evaluated combinations containing hydroquinone, tretinoin, and topical corticosteroids for melasma. Specific evidence is available for the combination of 2% hydroquinone, 0.025% tretinoin, and 0.1% mometasone. In one clinical study involving patients with melasma, this combination was applied once daily for six weeks and assessed using melasma severity and quality-of-life measures.
A separate safety study evaluated a mometasone-based triple combination in 60 patients with melasma and highlighted the potential for local adverse effects with prolonged use. These findings support limiting treatment duration and using the medication under dermatological supervision. (PubMed Central (PMC))
Modern dermatology reviews also recognize triple combinations containing hydroquinone, tretinoin, and a corticosteroid as an option for topical melasma management. However, formulations vary in the concentrations and types of their active ingredients, so results from one formulation should not automatically be attributed to every product containing similar ingredients. (Springer)
MELALITE XL should not be considered a general-purpose cosmetic skin-lightening product. Prolonged or uncontrolled use of topical corticosteroids may increase the risk of skin atrophy, visible small blood vessels, and other local complications. (PubMed Central (PMC))
MELALITE XL is used for the short-term treatment of moderate to severe facial melasma. The treatment is intended to reduce the appearance of hyperpigmented patches and promote a more even skin tone.
Hydroquinone suppresses melanin production, tretinoin promotes epidermal renewal and can improve hydroquinone penetration, while mometasone furoate provides an anti-inflammatory effect. Together, these ingredients target several mechanisms involved in the development and persistence of melasma.
MELALITE XL is for external use only. Apply a thin layer to the affected areas as directed by a physician, usually in the evening. Clean and thoroughly dry the skin before application and wash the hands afterward unless the hands are being treated. Avoid contact with the eyes, lips, mucous membranes, broken skin, or severely irritated areas. During treatment, minimize exposure to sunlight and ultraviolet radiation and use appropriate sun protection as recommended by a healthcare professional. Do not increase the amount applied or extend the treatment period without medical advice.
Side Effects
If severe irritation, swelling, blistering, worsening inflammation, or other unusual reactions occur, discontinue use and consult a healthcare professional.
